Eosinophil maturation pathway

The eosinophil maturation pathway, also known as eosinophilopoiesis, is the biological process by which hematopoietic stem cells in the bone marrow differentiate into mature eosinophils (Source: PubMed, PMID: 16461133). This process is primarily regulated by a triad of cytokines: Interleukin-3 (IL-3), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), and most critically, Interleukin-5 (IL-5) (Source: StatPearls, NBK542180). IL-5 is the most specific factor for the eosinophil lineage, driving the expansion and maturation of eosinophil progenitors (Source: Journal of Allergy and Clinical Immunology). In pathological states such as severe asthma or hypereosinophilic syndromes, overactivation of this pathway leads to excessive eosinophil production and tissue infiltration, causing chronic inflammation and organ damage (Source: NIH, National Heart, Lung, and Blood Institute). Therapeutic strategies often target this pathway by using monoclonal antibodies like Mepolizumab or Reslizumab to neutralize IL-5, or Benralizumab to block the IL-5 receptor alpha (IL-5Rα), thereby reducing systemic and local eosinophil levels (Source: FDA.gov). Because this entry describes a multi-step biological process involving several distinct molecular targets rather than a single receptor or enzyme, it is classified as a pathway (Source: UniProt).

Other names

EosinophilopoiesisEosinophil differentiation pathway

Inhibition of Interleukin-5 (IL-5) or the Interleukin-5 receptor alpha (IL-5Rα) to suppress eosinophil differentiation, recruitment, and survival.